Related Experiment Videos
Randomized trials of adjuvant and neoadjuvant chemotherapy in bladder cancer
1Department of Clinical Therapeutics, University of Athens School of Medicine, Greece.
Abstract:
Data of randomized studies of adjuvant and neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer were reviewed. Four adjuvant studies have been published. The interpretation of their data is compromised primarily because of small patient numbers. Thus, a possible survival advantage cannot be documented, and significantly larger, prospective studies are needed. However, there is some evidence of improved disease-free survival for patients with non-organ-confined tumors treated with cisplatin-based combination chemotherapy. More data are available for neoadjuvant chemotherapy. The already published randomized studies, including a large trial of who was designed to detect a 10% survival benefit, do not indicate a significant advantage for neoadjuvant chemotherapy. Radical cystectomy remains the standard treatment to which other therapeutic modalities must be compared.
Insights
Adjuvant chemotherapy shows potential disease-free survival benefits for muscle-invasive bladder cancer patients with non-organ-confined tumors. However, neoadjuvant chemotherapy offers no significant survival advantage, necessitating further research.
Area of Science:
- Urology
- Oncology
- Clinical Trials
Background:
- Muscle-invasive bladder cancer (MIBC) treatment often involves multimodal approaches.
- Adjuvant and neoadjuvant chemotherapy are investigated as adjuncts to radical cystectomy.
- Evidence regarding the efficacy of these chemotherapy strategies remains under evaluation.
Purpose of the Study:
- To review randomized studies on adjuvant and neoadjuvant chemotherapy for MIBC.
- To assess the survival benefits and limitations of current chemotherapy data.
- To determine the role of chemotherapy in comparison to radical cystectomy.
Main Methods:
- Systematic review of published randomized studies.
- Analysis of data from adjuvant and neoadjuvant chemotherapy trials in MIBC patients.
- Evaluation of survival data, including overall survival and disease-free survival.
Main Results:
- Adjuvant chemotherapy data are limited by small patient numbers, precluding definitive survival advantage documentation.
- Some evidence suggests improved disease-free survival with cisplatin-based adjuvant chemotherapy for non-organ-confined tumors.
- Published randomized trials, including a large WHO study, do not demonstrate a significant survival advantage for neoadjuvant chemotherapy.
Conclusions:
- Larger prospective studies are required to confirm adjuvant chemotherapy benefits in MIBC.
- Neoadjuvant chemotherapy does not currently show a significant survival advantage over standard treatment.
- Radical cystectomy remains the established standard treatment for muscle-invasive bladder cancer.